Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18 at 2:20 PM ET. The event aims to discuss advancements in treatments for serious diseases, focusing on their lead product, VRDN-001, targeting thyroid eye disease (TED). This condition can cause severe complications, necessitating surgical interventions. A live webcast and replay of the chat will be available on Viridian's website.

WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in a Fireside Chat at the SVB Leerink 11^th Annual Global Healthcare Conference on February 18 at 2:20pm ET.

The live webcast and a replay of the Fireside Chat can be accessed under “Events” in the Investors section of the Viridian Therapeutics, Inc. website.

About Viridian Therapeutics, Inc.

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian’s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact:
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com 

FAQ

When will Jonathan Violin participate in the Fireside Chat?

Jonathan Violin will participate in the Fireside Chat on February 18 at 2:20 PM ET.

What is the focus of Viridian Therapeutics' product VRDN-001?

VRDN-001 targets the insulin-like growth factor-1 receptor for treating thyroid eye disease (TED).

What is thyroid eye disease (TED)?

Thyroid eye disease is an autoimmune condition causing inflammation around the eyes, leading to potential blindness.

How can I access the webcast of the Fireside Chat?

The live webcast and replay will be available in the Investors section of the Viridian Therapeutics website.

What is VRDN's second product candidate?

VRDN's second product candidate is VRDN-002, designed for low-volume subcutaneous injection with half-life extension.